The purpose of this study is to show that two FDA-approved botulinum toxin drugs called
Xeomin® and Botox® can reduce the severity of vertical lines (wrinkles) that appear between
the eyebrows (glabellar frown lines).
Phase:
Phase 4
Details
Lead Sponsor:
Merz North America, Inc. Merz Pharmaceuticals, LLC
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA